6 citations
,
November 2010 in “International Journal of Andrology” New oral testosterone formulations show potential for safer, effective hormone replacement in men with low testosterone.
4 citations
,
August 2011 in “The Lancet Oncology” Off-label drug use can be risky and requires careful consideration to ensure patient safety.
24 citations
,
June 2013 in “Expert opinion on pharmacotherapy” Dutasteride effectively treats benign prostatic hyperplasia but isn't approved for preventing prostate cancer.
The vitamin D receptor has many roles in the body beyond managing calcium, affecting the immune system, hair growth, muscles, fat, bone marrow, and cancer cells.
24 citations
,
September 2002 in “Der Urologe” A stronger dual 5α-reductase inhibitor could improve treatment for benign prostatic hyperplasia by further reducing DHT levels.
164 citations
,
January 2003 in “Drugs”
Equine Cushing's disease in horses causes hormonal imbalance, leading to symptoms like abnormal hair growth and requires lifelong treatment with pergolide.
59 citations
,
April 2016 in “Breast Cancer Research and Treatment” Targeting vitamin D and androgen receptors may effectively treat triple-negative breast cancer, especially with chemotherapy.
5 citations
,
March 2021 in “Hepatitis Monthly” Tenofovir alafenamide fumarate is effective and safer for hepatitis B, with fewer side effects than tenofovir disoproxil fumarate.
30 citations
,
June 2010 in “Endocrine Related Cancer” SRD5A1 is crucial in advanced prostate cancer, and blocking both SRD5A1 and SRD5A2 is more effective than targeting SRD5A2 alone.